Terminalia arjuna Enhances Baroreflex Sensitivity and Myocardial Function in Isoproterenol-Induced Chronic Heart Failure Rats

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 17, Issue 2, 2012, Pages 199-207

  Parveen, Adila ^a,b   Babbar, Rashmi ^b   Agarwal, Sarita ^b   Kotwani, Anita ^a   Fahim, Mohammad ^a,c  

^a UNIVERSITY OF DELHI   (India)

^b MAULANA AZAD MEDICAL COLLEGE   (India)

^c HAMDARD UNIVERSITY   (India)

Author keywords

baroreflex sensitivity; chronic heart failure; inflammation; left ventricle functions; oxidative stress; Terminalia arjuna

Indexed keywords

ANTIOXIDANT; CYTOKINE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDOLE DERIVATIVE; ISOPRENALINE; MONOUNSATURATED FATTY ACID; NITROPRUSSIDE SODIUM; PHENYLEPHRINE; PLANT EXTRACT;

ANIMAL; ARTICLE; BARK; CHEMISTRY; CHRONIC DISEASE; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECT; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; MALE; METABOLISM; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRESSORECEPTOR REFLEX; RAT; TERMINALIA; WISTAR RAT;

ANIMALS; ANTIOXIDANTS; BAROREFLEX; CHRONIC DISEASE; CYTOKINES; DISEASE MODELS, ANIMAL; FATTY ACIDS, MONOUNSATURATED; FEMALE; HEART FAILURE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; ISOPROTERENOL; MALE; NITROPRUSSIDE; OXIDATIVE STRESS; PHENYLEPHRINE; PLANT BARK; PLANT EXTRACTS; RATS; RATS, WISTAR; TERMINALIA; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84867147641     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248411416816     Document Type: Article

References (48)

1. Landmesser U Drexler H. Endothelial dysfunction, heart failure, and ACE inhibition. Medicographia. 2006; 28(4):361-364.
2. Middlekauff HL. Mechanisms and implications of autonomic nervous system dysfunction in heart failure. Curr Opin Cardiol. 1997; 12(3):265-275.
3. Packer M. Pathophysiology of chronic heart failure. Lancet. 1992; 340(8811):88-92.
4. DiBona GF Sawin LL. Increased renal nerve activity in cardiac failure: arterial vs. cardiac baroreflex impairment. Am J Physiol. 1995; 268(1 pt 2):112-116.
5. Creager MA Creager SJ. Arterial baroreflex regulation of blood pressure in patients with congestive heart failure. J Am Coll Cardiol. 1994; 23(2):401-405.
6. La Rovere MT Bigger JT Jr Marcus FI Mortara A Schwartz PJ. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators. Lancet. 1998; 351(9101):478-484.
7. Cohn JN Ferrari R Sharpe N. Cardiac remodelling—concepts and clinical implications: a consensus paper from an international forum on cardiac remodelling. Behalf of an international forum on cardiac remodelling. J Am Coll Cardiol. 2000; 35(3):569-582.
8. Go AS Lee WY Yang J Lo JC Gurwitz JH. Statin therapy and risks for death and hospitalization in chronic heart failure. JAMA. 2006; 296(17):2105-2111.
9. Liao JK Laufs U. Pleiotropic effects of statins. Ann Rev Pharmacol Toxicol. 2005; 45(Feb):89-118.
10. Pliquett RU Cornish KG Peuler JD Zucker IH. Simvastatin normalizes autonomic neural control in experimental heart failure. Circulation. 2003; 107(19):2493-2498.
11. Grundy SM. The issue of statin safety: where do we stand? Circulation. 2005; 111(23):3016-3019.
12. Gotto AM. Statins, cardiovascular disease and drug safety. Am J Cardiol. 2006; 97(8A):3-5.
13. Gupta R Singhal S Goyle A Sharma VN. Antioxidant and hypocholesterolaemic effects of Terminalia arjuna tree-bark powder: a randomised placebo-controlled trial. J Assoc Physicians India. 2001; 49(Feb):231-235.
14. Kaur S Grover IS Kumar S. Anti mutagenic potential of extracts isolated from Terminalia arjuna. J. Environ Pathol Toxicol Oncol. 2001; 20(1):9-14.
15. Avinash N Laxman SM Satwinderject K Iqbal SG Renu W, Sunil CK. Growth suppression of human transformed cells by treatment with bark extracts from a medicinal plant Terminalia ajunain vitro cell Dev Biol Animal. 2000; 36(8):544-547.
16. Takahashi S Tanaka H Hano V Ito K Nomura T Shigenobu K. Hypotensive effect in rats of hydrophilic extract from Terminalia arjuna containing tannin, related compounds. Phytother Res. 1997; 11(6):424-427.
17. Dwivedi S. Antianginal and cardioprotective effects of Terminalia arjuna, an indigenous drug, in coronary heart disease. J Assoc Physicians India. 1994; 42(4):287-289.
18. Gauthaman K Maulik M Kumari R Manchanda SC Dinda AK Maulik SK. Effect of chronic treatment with bark of Terminalia arjuna: a study on the isolated ischemic-reperfused rat heart. J Ethnopharmacol. 2001; 75(2-3):197-201.
19. Teerlink JR Pfeffer JM Pfeffer MA. Effect of left ventricular sphericity on the evolution of ventricular dysfunction in rats with diffuse isoproterenol-induced myocardial necrosis. J Cardiac Failure. 1998; 4(1):45-56.
20. Grimm D Elsner D Schunkert H, et al. Development of heart failure following isoproterenol administration in the rat: role of the rennin-angiotensin system. Cardiovasc Res. 1998; 37(1):91-100.
21. Tauseef M Sharma KK Fahim M. Aspirin restores normal baroreflex function in hypercholesterolemic rats by its antioxidative action. Eur J Pharmacol. 2007; 556(1-3):136-143.
22. Wright JR Colby HD Miles PR. Cytosolic factors that affect microsomal lipid peroxidation in lung and liver. Arch Biochem Biophys. 1981; 206(2):296-304.
23. Jollow DJ Mitchell JR Zampaglione N Gillette JR. Bromobenzene induced liver necrosis: protective role of glutathione and evidence for 3,4-bromobenzene oxide as the hepatotoxic metabolite. Pharmacology. 1974; 11(3):151-169.
24. Bos R Mougenot N Mediani O Vanhoutte PM Lechat P. Potassium canrenoate, an aldosterone receptor antagonist, reduces isoprenaline-induced cardiac fibrosis in the rat. J Pharmacol Exp Ther. 2004; 309(3):1160-1166.
25. Zhang GX Kimura S Nishiyama A, et al. Cardiac oxidative stress in acute and chronic isoproterenol-infused rats. Cardiovasc Res. 2005; 65(1):230-238.
26. Balakumar P Singh M. The possible role of caspase-3 in pathological and physiological cardiac hypertrophy in rats. Basic Clin Pharmacol Toxicol. 2006; 99(6):418-424.
27. Krishnamurthy P Subramanian V Singh M Singh K. Deficiency of beta 1 integrins results in increased myocardial dysfunction after myocardial infarction. Heart. 2006; 92(9):1309-1315.
28. Teerlink JR Pfeffer JM Pfeffer MA. Progressive ventricular remodeling in response to diffuse isoproterenol induced myocardial necrosis in rats. Circ Res. 1994; 75(1):105-113.
29. Zucker IH Schultz HD Li YF, Wang Y., Wang W., Patel K.P. The origin of sympathetic outflow in heart failure: the roles of angiotensin II and nitric oxide. Prog Biophys Mol Biol 2004; 84(2-3):217-232.
30. Zhou R Xu Q Zheng P Yan L Zheng J Dai G. Cardioprotective effect of fluvastatin on isoproterenol-induced myocardial infarction in rat. Eur J Pharmacol. 2008; 586(1-3):244-250.
31. Liao JK. Statin therapy for cardiac hypertrophy and heart failure. J Investig Med. 2004; 52(4):248-253.
32. Kumar S Enjamoori R Jaiswal A Ray R Seth S Maulik SK. Catecholamine-induced myocardial fibrosis and oxidative stress is attenuated by Terminalia arjuna (Roxb.). J Pharm Pharmacol. 2009; 61(11):1529-1536.
33. Sugihara N Arakawa T Ohnishi M Furuno K. Anti-andpro-oxidative effects of flavonoids on metal-induced lipid hydro peroxide-dependent lipid peroxidation in cultured hepatocytes loaded with a-linolenic acid. Free Radic Biol Med. 1999; 27(11-12):1313-1323.
34. Rostagnoa C Galantia G Felicia F, et al. Prognostic value of baroreflex sensitivity assessed by phase IV of Valsalva manoeuvre in patients with mild-to-moderate heart failure. Eur J Heart Fail. 2000; 2(1):41-45.
35. Mortara A La Rovere MT Pinna GD, et al. Arterial baroreflex modulation of heart rate in chronic heart failure: clinical and hemodynamic correlates and prognostic implications. Circulation. 1997; 96(10):3450-3458.
36. Gao L Wang W Li YL, et al. Simvastatin therapy normalizes sympathetic neural control in experimental heart failure: roles of angiotensin II type 1 receptors and NAD(P)H oxidase. Circulation. 2005; 112(12):1763-1770.
37. Gao L Wang W Zucker IH. Simvastatin inhibits central sympathetic outflow in heart failure by a nitric-oxide synthase mechanism. J Pharmacol Exp Ther. 2008; 326(1):278-285.
38. Takimoto E Kass DA. Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension. 2007; 49(2):241-248.
39. Rathore N John S Kale M Bhatnagar D. Lipid peroxidation and antioxidant enzymes in isoproterenol induced oxidative stress in rat tissues. Pharmacol Res. 1998; 38(4):297-303.
40. Li Z Mao HZ Abboud FM Chapleau MW. Oxygen-derived free radicals contribute to baroreceptor dysfunction in atherosclerotic rabbits. Circ Res. 1996; 79(4):802-811.
41. Schultz HD Ustinova EE. Capsaicin receptors mediate free radical-induced activation of cardiac afferent endings. Cardiovasc Res. 1998; 38(2):348-355.
42. Bozkurt B Kribbs SB Clubb FJ, et al. Pathophysiologically relevant concentrations of tumour necrosis factor-α promote progressive left ventricular dysfunction and remodeling in rats. Circulation. 1998; 97(14):1382-1391.
43. Torre-Amione G. Immune activation in chronic heart failure. Am J Cardiol. 2005; 95(11A):3-8.
44. Mann DL. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res. 2002; 91(11):988-998.
45. Nakamura K Fushimi K Kuochi H, et al. Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-alpha and angiotensin II. Circulation. 1998; 98(8):794-799.
46. Bone K. Clinical Applications of Ayurvedic and Chinese Herbs. Warwick, Queensland: Phytotherapy Press, 1996; 131-133.
47. Terminalia arjuna. Altern Med Rev Monographs. 1999; 4(6):411-415.
48. Huk I Brovkovych V Weigel G, et al. Bioflavonoid quercetin scavengers superoxide and increases nitric oxide contraction in ischemic reperfusion injury: an experimental study. B J Surg. 1998; 85(8):1080-1085.